Hemodynamic intelligence for primary care
See the cause behind every blood-pressure number.
An FDA-cleared, non-invasive test in the exam room you already have. The physician sees why pressure is high, chooses therapy that fits, and confirms it is working. Control in weeks, not months.
The toll
Nearly half of all US adults suffer from Hypertension. Most are not controlled. It costs $131–198B a year.
125.9M
US adults with hypertension, rising to 6 in 10 by 2050
~100M
not controlled; fewer than 1 in 20 adults under 40 are controlled
680,179
deaths in 2024 linked to hypertension
~4 in 10
adults with hypertension don't know they have it
$131–198B
cost to the US every year
~$1,920
extra medical spending per patient, every year
$56.2B
a year in stroke costs
$1.8T
cardiovascular costs by 2050, nearly triple today
Every month uncontrolled adds risk and cost. NICaS helps close the gap in weeks.
Sources: AHA 2026 Heart Disease & Stroke Statistics; NCHS Data Brief 511 (2021–2023); CDC WONDER (2024 deaths); CDC, High Blood Pressure; Kirkland et al., JAHA 2018; CDC Stroke Facts; Joynt Maddox et al., Circulation 2024.
How it works
Three steps, one visit to start.
1. Test
A quick, non-invasive NICaS test during a routine visit, using sensors on the wrist and ankle.
2. See the cause
The physician sees which pattern is driving high pressure: vasoconstriction (tight vessels), hyperdynamic (the heart pumping too hard) or mixed.
3. Treat and confirm
The physician chooses therapy that fits, then retests to confirm it is working.
Why care fails
Standard care treats the number. NICaS shows the cause.
Standard care
Drug choice
By guideline and trial and error
Adjusting
Wait a month, then add or switch drugs
Time
About half controlled at 6 months
Visits
Every failed try means another visit
NICaS-guided care
Drug choice
Guided by the patient's measured profile
Adjusting
A repeat test shows if the therapy is working
Time
3 in 4 controlled in about 30 days
Visits
About 2 fewer visits per patient
Barrett et al., Hypertension 2025 (usual care); Cleland et al., Am J Med 2026 (lead site, <140/90; observational).
The proof
Published in the American Journal of Medicine.
Cleland JGF, Romer DE, et al. Effect of routinely tailoring anti-hypertensive therapy to hemodynamic profile in primary care. American Journal of Medicine, 2026.
14,058
primary-care patients
10 years, two US groups
3 in 4
controlled in about 30 days
lead site, <140/90
92%
controlled by the second visit
lead site, <140/90
3 in 4 controlled in 2 visits, about 30 days.
Observational study, funded by IMS and MedsEngine. A US randomized trial is planned.
The platform
One connected system, from test to lasting control.
Measure
FDA-cleared NICaS hemodynamic test in the exam room.
Understand
MedsEngine decision support organizes the findings. The physician decides.
Prove
Cloud analytics track control rates across patients and sites.
Sustain
24/7 live clinical support for practice teams, while the patient is still in the room.
Device, clinical decision support, analytics and 24/7 support, delivered as one fully integrated system with Epic and Athena.
NICaS informs. The physician decides.
Who we serve
Built for organizations accountable for blood pressure.
ACOs
Lift hypertension control across your attributed population.
Learn moreMedicare Advantage Plans
Support blood-pressure quality measures with faster control.
Learn moreIntegrated Delivery Systems
Bring one consistent approach to every primary-care clinic.
Learn moreSelf-funded employers
Help employees get blood pressure under control sooner.
Learn moreWhy HDI
Four reasons partners choose us.
Physician-led
NICaS informs. The physician decides, every time.
FDA-cleared technology
A proven, non-invasive test from InnovaMed Sphere.
Full-service platform
Device, decision support, analytics and clinical services in one.
Built for primary care
Fits the exam room and workflow you already have.
Our founders
Dixon Thayer
Managing Partner
Dr. Jay Rosan
Co-Founder
Mark Dumoff
Co-Founder